Astrazeneca plc ADR (NASDAQ:AZN) shares, rose in value on Thursday, April 04, with the stock price up by 2.07% to the previous day’s close as strong demand from buyers drove the stock to $68.19.
Actively observing the price movement in the recent trading, the stock is buoying the session at $66.81. The value of beta (5-year monthly) is 0.17 whereas the PE ratio is 35.73 over 12-month period. Referring to stock’s 52-week performance, its high was $76.56, and the low was $60.47. On the whole, AZN has fluctuated by 5.22% over the past month.
The company’s Forward Dividend Ratio is 1.45, with its dividend yield at 2.13%. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $1.25, which is expected to increase to $1.96 for fiscal year $3.88 and then to about $4.38 by fiscal year 2025. Data indicates that the EPS growth is expected to be 6.90% in 2025, while the next year’s EPS growth is forecast to be 12.90%.
Analysts have estimated the company’s revenue for the quarter at $12.01 billion, with a low estimate of $11.76 billion and a high estimate of $12.44 billion. According to the average forecast, sales growth in current quarter could jump up 13.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $50.76 billion, representing an increase of 10.80% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 1 upward and no downward review(s) in last seven days. We see that AZN’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of Hold while long term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 2.73, with the price of AZN currently trading nearly 2.31% and 3.77% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 60.98, while the 7-day volatility ratio is showing 1.42% which for the 30-day chart, stands at 1.19%. Furthermore, Astrazeneca plc ADR (AZN)’s beta value is 0.53, and its average true range (ATR) is 1.05.
A comparison of Astrazeneca plc ADR (AZN) with its peers suggests the former has fared considerably weaker in the market. AZN showed an intraday change of 2.07% in today’s session so far, and over the past year, it shrunk by -2.45%%.
Data on historical trading for Astrazeneca plc ADR (NASDAQ:AZN) indicates that the trading volumes over the past 10 days have averaged 4.39 million and over the past 3 months, they’ve averaged 6.21 million. According to company’s latest data on outstanding shares, there are 3.10 billion shares outstanding.
Nearly 0.03% of Astrazeneca plc ADR’s shares belong to company insiders and institutional investors own 15.98% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 9.26 million shares as on Mar 15, 2024, resulting in a short ratio of 1.87. According to the data, the short interest in Astrazeneca plc ADR (AZN) stood at 0.34% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 8.92 million. The stock has risen by 1.25% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AZN stock heading into the next quarter.
